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PVascular Disease
GCH1 Haplotype Determines Vascular and
Plasma Biopterin Availability in Coronary Artery Disease
Effects on Vascular Superoxide Production and Endothelial Function
Charalambos Antoniades, MD, PHD,* Cheerag Shirodaria, MRCP,* Tim Van Assche, PHD,*
Colin Cunnington, MRCP,* Irmgard Tegeder, MD, PHD,†‡ Jörn Lötsch, MD, PHD,‡
Tomasz J. Guzik, MD, PHD,*§ Paul Leeson, MRCP, PHD,* Jonathan Diesch, HNC,*
Dimitris Tousoulis, MD, PHD, FACC,¶ Christodoulos Stefanadis, MD, FACC, FESC,¶
Michael Costigan, PHD, Clifford J. Woolf, MD, PHD,† Nicholas J. Alp, MD, PHD, MRCP,*
Keith M. Channon, MD, FRCP*
Oxford, United Kingdom; Boston, Massachusetts; Frankfurt am Main, Germany; Cracow, Poland; and Athens, Greece
Objectives This study sought to determine the effects of endogenous tetrahydrobiopterin (BH4) bioavailability on endothe-
lial nitric oxide synthase (eNOS) coupling, nitric oxide (NO) bioavailability, and vascular superoxide production in
patients with coronary artery disease (CAD).
Background GTP-cyclohydrolase I, encoded by the GCH1 gene, is the rate-limiting enzyme in the biosynthesis of BH4, an
eNOS cofactor important for maintaining enzymatic coupling. We examined the associations between haplo-
types of the GCH1 gene, GCH1 expression and biopterin levels, and the effects on endothelial function and vas-
cular superoxide production.
Methods Blood samples and segments of internal mammary arteries and saphenous veins were obtained from patients with
CAD undergoing coronary artery bypass grafting (n 347). The GCH1 haplotypes were defined by 3 polymorphisms:
rs8007267GA, rs3783641AT, and rs10483639CG (X haplotype: A, T, G; O haplotype: any other combination).
Vascular superoxide ( the eNOS inhibitor NG-nitro-L-arginine methyl ester [L-NAME]) was measured by lucigenin-
enhanced chemiluminescence, whereas the vasorelaxations of saphenous veins to acetylcholine were evaluated ex vivo.
Results Haplotype frequencies were OO 70.6%, XO 27.4%, and XX 2.0%. The X haplotype was associated with significantly
lower vascular GCH1 messenger ribonucleic acid expression and substantial reductions in both plasma and vas-
cular BH4 levels. In X haplotype carriers both vascular superoxide and L-NAME–inhibitable superoxide were sig-
nificantly increased, and were associated with reduced vasorelaxations to acetylcholine.
Conclusions GCH1 gene expression, modulated by a particular GCH1 haplotype, is a major determinant of BH4 bioavailability both
in plasma and in the vascular wall in patients with CAD. Genetic variation in GCH1 underlies important differences in
endogenous BH4 availability and is a determinant of eNOS coupling, vascular redox state, and endothelial function in
human vascular disease. (J Am Coll Cardiol 2008;52:158–65) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.062v
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iaintenance of endothelial function is a critical aspect of
ascular homeostasis. Loss of normal endothelial production
f nitric oxide (NO) is an early and characteristic feature of
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ersity of Oxford, Oxford, United Kingdom; †Neural Plasticity Research Group,
epartment of Anesthesia and Critical Care, Massachusetts General Hospital and
arvard Medical School, Boston, Massachusetts; ‡Pharmazentrum Frankfurt/ZAFES,
nstitute for Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am
ain, Germany; §Departments of Medicine and Pharmacology, Jagiellonian University,
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Manuscript received November 2, 2007; accepted December 12, 2007.ascular disease states and plays a role in disease pathogen-
sis (1). Endothelial nitric oxide synthase (eNOS) is regu-
See page 166
ated by the cofactor tetrahydrobiopterin (BH4) (2). Re-
uced BH4 availability in disease states seems to be an
mportant aspect of impaired eNOS activity and increased
ascular superoxide production (1,2). In humans with vas-
ular disease states, acute administration of BH4 can im-
rove endothelial function (3,4), and treatments such as
olates or vitamin C, which improve endothelial function,
ay exert some of their effects by increasing BH4 availabil-
ty (5–9). However, the extent to which alterations in endog-
nous BH4 availability, rather than pharmacologic effects of
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unction in humans in vivo remains unclear.
GTP cyclohydrolase I (GTPCH) is the rate-limiting en-
yme in the biosynthesis of BH4 (10), and is a major
eterminant of BH4 levels, through transcriptional regulation
f GCH1 expression. In some experimental models of vascular
isease, reduced BH4 is associated with reduced GTPCH
rotein levels, suggesting reduced BH4 biosynthesis (11).
owever, BH4 oxidation by free radicals such as peroxynitrite
ONOO), generating dihydrobiopterin (BH2) and biopterin
B), may cause loss of BH4 without changes in biopterin
ynthesis (5,7,12). The relative importance of synthesis versus
xidation of BH4 in atherosclerosis is complex because both
ocal and systemic inflammation up-regulate GCH1 expression
13) but also increase ONOO production, potentially result-
ng in greater BH4 oxidation (14).
In genetic mouse models, constitutive reduction in GCH1
xpression causes BH4 deficiency, resulting in abnormal
NOS regulation (14–16). Conversely, transgenic overex-
ression of GTPCH in the vascular endothelium is suffi-
ient to augment vascular BH4 levels (17), improve endo-
helial function in models of vascular disease (14), and
escue the vascular effects of genetic BH4 deficiency (16).
hus, in experimental models, genetic alteration of endog-
nous BH4 biosynthesis has provided useful insights into
he role of BH4 in vascular disease pathogenesis. In con-
rast, it is unknown whether alterations in endogenous BH4
ynthesis in humans are sufficient to alter systemic or
ascular BH4 availability, or have any impact on vascular
unction.
We have recently identified a novel haplotype of the
CH1 gene that is associated with significantly lower
TPCH activity in stimulated leukocytes (18,19). This
aplotype is defined by 3 single nucleotide polymor-
hisms: rs8007267GA in the putative promoter region,
s3783641AT in intron 1 and rs10483639CG in the 3=
ntranslated region of the GCH1 gene (18,19).
In this study we examined the functional effects of this
CH1 haplotype on the levels of BH4 and total biopterins
oth in plasma and in vessels obtained from patients with
oronary artery disease (CAD). Furthermore, we investi-
ated how intrinsic genetic variation in vascular BH4
iosynthesis alters regulation of eNOS function in the
uman vasculature through effects on superoxide production
nd NO-mediated endothelial function.
ethods
tudy subjects. We studied 347 patients with CAD un-
ergoing elective coronary artery bypass grafting (CABG) at
he John Radcliffe Hospital, Oxford, United Kingdom.
xclusion criteria were any inflammatory, infective, liver, or
enal disease; malignancy; acute coronary event during the
ast 2 months; or clinically overt heart failure. Patients
eceiving nonsteroidal anti-inflammatory drugs, dietary sup-
lements of folic acid, or antioxidant vitamins were also pxcluded. Demographic charac-
eristics of the patients are pre-
ented in Table 1. The study was
pproved by the local research
thics committee, and each patient
ave written informed consent.
lasma and tissue samples.
lood samples were obtained im-
ediately before surgery, after
vernight fasting. Samples were
entrifuged at 2,500 rpm for 10
in, and serum or plasma was
tored at 80oC until assayed.
amples of saphenous vein (SV)
nd internal mammary artery
IMA) were obtained at the time
f CABG surgery, as we have
reviously described (5,20). Paired
essel segments were snap-frozen
nd stored at 80oC for mea-
urement of biopterin content, or
ere transferred to the laboratory
or functional studies within 30
in, in ice cold Krebs-Henseleit
uffer (5,20).
eoxyribonucleic acid (DNA)
xtraction and genotyping.
enomic DNA was extracted
rom 2 ml of whole blood using
tandard methods (QIAamp
NA blood Midi kit, Qiagen,
ermantown, Maryland). In ad-
ition, DNA samples were available from 741 unrelated
ubjects of Caucasian ethnicity (mostly medical students)
ho had consented into genotyping and served as control
ubjects for allelic frequencies in the present study.
The DNA samples were screened for that particular
unctional GCH1 haplotype identified as being associated
ith decreased GCH1 expression and BH4 production in a
revious study (21). The complete haplotype consists of 15
NA positions of the GCH1 gene. However, as described
lsewhere (19), the diagnosis of the particular GCH1 hap-
otype of present interest is possible with 100% sensitivity
nd specificity by screening for just 3 GCH1 single-
ucleotide polymorphisms that span the entire DNA range
f the haplotype: c. –9610GA (dbSNP rs8007267GA)
n the 5= untranslated region, c.3438900AT (dbSNP
s3783641AT) in intron 1, and c.*4279 (dbSNP
s10483639CG) in the 3= untranslated region. Thus, for
iagnosis purposes the haplotype of interest reduces to
s8007267A/rs3783641T/rs10483639G. The GCH1 haplo-
ype of interest was identified by means of validated Pyrose-
uencing screening assays (Pyrosequencer PSQ95, Uppsala,
weden) diagnosing the 3 selected sodium nitroprussides
SNPs) (19). Two different types of positive control sam-
Abbreviations
and Acronyms
ACh  acetylcholine
BH4  tetrahydrobiopterin
BH2  dihydrobiopterin
B  biopterin
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CRP  C-reactive protein
eNOS  endothelial nitric
oxide synthase
GTPCH  GTP-
cyclohydrolase I
IMA  internal mammary
artery
L-NAME  NG-nitro-L-
arginine methyl ester
NO  nitric oxide
O2
  superoxide radical
ONOO  peroxynitrite
Ox-LDL  oxidized low-
density lipoprotein
RT-qPCR  real-time
quantitative polymerase
chain reaction
SNP  sodium
nitroprusside
SV  saphenous vein.les were implemented into all Pyrosequencing screening
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GCH1 Haplotypes and Vascular Biopterins July 8, 2008:158–65nalyses. One positive control set contained DNA sam-
les from carriers of the haplotype independently diagnosed
or all 15 GCH1 DNA positions by the 5=-exonuclease
ethod (22). The second set of positive controls consisted
f DNA samples homozygous or heterozygous for the
requent or rare alleles at the 3 SNP positions at the GCH1
NA, diagnosed externally by means of conventional se-
uencing (AGOWA GmbH, Berlin, Germany) (18,19).
ibonucleic acid (RNA) isolation and real-time quanti-
ative polymerase chain reaction (RT qPCR). Snap-
rozen vascular rings (IMA and SV) were initially lysed in
rizol reagent (Tri-Reagent, Sigma, St. Louis, Missouri),
ollowed by RNA purification from the aqueous phase using
he RNeasy Micro kit (Qiagen, Stanford, California). Ri-
onucleic acid was converted into complementary DNA
Superscript II reverse transcriptase, Invitrogen, Carlsbad,
alifornia), then subjected to qPCR using the TaqMan
ystem (Applied Biosystems, Foster City, California; Assay
D GCH  Hs00609198_m1, Assay ID GAPDH 
s02758991_g1) and analyzed on an iCyclerIQ (Biorad,
ercules, California). Relative expression was calculated using
he 2CT method.
etermination of plasma and vascular biopterin levels. BH4,
emographic Characteristics of Patients
Table 1 Demographic Characteristics of Patients
Number of patients 347
Male/female 292/55
Age (yrs) 65.42 0.49
Saphenous veins (n) 289
Internal mammary arteries (n) 166
Risk factors
Hypertension (%) 72.7
Hypercholesterolemia (%) 71.6
Smokers (current/ex) (%) 8.6/69.8
Diabetes mellitus (%) 27.5
Family history for coronary artery disease (%) 63.3
Body mass index (kg/m2) 28.04 0.34
Triglycerides (mmol/l) 1.65 0.09
Cholesterol (mmol/l) 4.07 0.08
High-density lipoprotein (mmol/l) 1.10 0.02
C-reactive protein (mg/l) 2.48 0.70
Plasma biopterin levels
Plasma tetrahydrobiopterin (nmol/l) 20.46 (10.13–41.86)
Plasma dihydrobiopterin (nmol/l) 15.19 (11.77–19.41)
Plasma biopterin (nmol/l) 4.09 (2.83–6.98)
Plasma total biopterins (nmol/l) 46.11 (30.04–71.33)
BH4/tBio ratio 0.49 0.018
Medication (%)
Statins 90.0
ACEI/ARB 66.0
Calcium-channel blockers 40.8
Beta-blocker 74.6
Aspirin 87.1
alues expressed as mean  SEM or median (25th to 75th percentile) unless otherwise noted.
ACEI  angiotensin-converting enzyme inhibitors; ARB  angiotensin receptor blockers; BH4 
etrahydrobiopterin; tBio  total biopterins.H2, and biopterin levels in plasma or vessel tissue lysates pere each determined separately from the same sample, by
igh-performance liquid chromatography followed by serial
lectrochemical and fluorescent detection, as previously
escribed (23). Total biopterins were quantified by sum-
ing BH4, BH2, and B. Biopterin levels were expressed as
mol/g of tissue for vessels and nmol/l for plasma.
etermination of vascular superoxide production. Vas-
ular superoxide production was measured in paired seg-
ents of SV using lucigenin-enhanced chemiluminescence
s previously described (5,24). Vessels were opened longi-
udinally to expose the endothelial surface and equilibrated
or 20 min in oxygenated (95% O2/5% CO2) Krebs-4-(2-
ydroxyethyl)-1-piperazine-ethane-sulfonic acid buffer (pH
7.4) at 37°C. Lucigenin-enhanced chemiluminescence
as measured using low-concentration lucigenin (5 mol/l)
25) because higher concentrations of lucigenin (up to 250
mol/l) favor redox cycling (24). As a measure of eNOS
oupling we determined NOS-derived superoxide produc-
ion, which was estimated as the difference in superoxide
roduction after 20 min incubation with the NOS inhibitor
G-nitro-L-arginine methyl ester (L-NAME) (100
mol/l).
asomotor studies. Endothelium-dependent and -independent
ilatations were assessed in SV obtained at the time of CABG,
sing isometric tension studies (5,26). Four rings from each
essel were pre-contracted with phenylephrine (3  106
mol/l), then endothelium-dependent relaxations were quan-
ified using acetylcholine (ACh, 109 to 105 mol/l).
inally, relaxations to the endothelium-independent NO
onor SNP (1010 to 106 mol/l) were evaluated in the
resence of L-NAME (100 mol/l) as we have previously
escribed (5,26).
etermination of oxidized low-density lipoprotein (ox-
DL) and C-reactive protein (CRP) levels. Serum levels
f ox-LDL were measured by enzyme-linked immunosor-
ent assay using commercially available kit (Mercodia,
weden). Serum levels of CRP were measured by immu-
onephelometry using a high-sensitivity method (Dade
ehring Marburg GmbH, Marburg, Germany).
tatistical analysis. GCH1 haploblocks and linkage dis-
quilibrium among the 3 SNPs with parameters D= and r2
27,28) were analyzed using the solid spine of LD algorithm
mplemented in Haploview (29). Allelic frequencies of the
atient cohorts were compared with those observed in a
andom sample of 741 healthy unrelated control subjects of
aucasian ethnicity (mainly medical students of the Uni-
ersity of Frankfurt am Main, Germany) by means of the
isher exact test. On the basis of the observed allelic
requency, the expected number of homozygous and het-
rozygous carriers of the respective SNP was calculated
sing the Hardy-Weinberg equation as p2  2pq  q2  1,
here p and q are defined as the probabilities of occurrence
or the dominant and mutated alleles, respectively (30). The
orrespondence between the observed numbers of homozy-
ous and heterozygous individuals and the numbers ex-
ected on the basis of the Hardy-Weinberg equilibrium,
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July 8, 2008:158–65 GCH1 Haplotypes and Vascular Biopterinsndicating that the study sample corresponded to a random
ample of subjects, was assessed using the chi-square good-
ess of fit test. Allelic frequencies of the cohort of 347
atients were compared with those observed in a random
ample of 741 healthy unrelated control subjects of Cauca-
ian ethnicity (mainly medical students of the University of
rankfurt am Main, Germany) by means of the Fisher exact
est. Between these cohorts, the number of noncarriers,
omozygous carriers, and heterozygous carriers of the par-
icular GCH1 haplotype were compared using chi-square
tatistics.
All variables were tested for normal distribution using the
olmokorov-Smirnov test. Normally distributed variables
re presented as mean  SEM, whereas nonnormally
istributed variables were log-transformed for analysis and
re presented as median [25th to 75th percentiles] and
ange. Comparisons of baseline and demographic charac-
eristics among the 3 genotypes were performed using
ne-way analysis of variance for multiple comparisons,
hereas an unpaired t test was used to compare variables
etween 2 groups (for recessive models).
Univariate analysis was performed by calculation of the
earson coefficient. Multivariate analysis was used to exam-
ne the effect of the genotype on vascular/plasma biopterins,
ascular superoxide, L-NAME–induced change of vascular
uperoxide, or maximum relaxations to ACh as dependent
ariables. As independent variables we used GCH1 geno-
ype, and those clinical characteristics (age, gender, diabetes
ellitus, smoking, dyslipidemia, hypertension, body mass
ndex, and medications) that showed an association with the
ependent variable in univariate analysis at the level of 15%.
backward elimination procedure was applied in all mod-
ls, having p  0.1 as the threshold to remove a variable
rom the model. All p values were 2-tailed, and a value of
 0.05 was considered statistically significant. All statis-
ical analyses were performed using SPSS version 12.0
SPSS Inc., Chicago, Illinois).
esults
e defined GCH1 haplotypes in 347 patients with CAD
nd 741 control subjects. In CAD patients, the 3 SNPs used
o define the haplotypes were in linkage disequilibrium.
pecifically, values of D= and r2 were 95 and 77 for
s8007267 and rs3783641, 87 and 69 for rs3783641 and
s10483639, and 86 and 5 for rs8007267 and rs10483639,
espectively. The 3 SNPs were located within 1 single
aploblock (29). The numbers of 245 noncarriers (OO) and
5 heterozygous (XO) and 7 homozygous (XX) carriers of
he GCH1 X haplotype was in accordance with the Hardy-
einberg law (chi-square goodness of fit test: p  0.81).
ardy-Weinberg equilibrium also applied to the control
ubjects (OO, n  543; XO, n  178; XX, n  20;
hi-square goodness of fit test: p  0.51). The allelic
requencies of the GCH1 X haplotype of 15.7 and 14.7 in
atients and healthy control subjects, respectively, did notiffer between groups (Fisher exact test: p  0.56). More-
ver, the numbers of noncarriers and heterozygous and
omozygous carriers of the GCH1 X haplotype were similar
n patients and control subjects (chi-square test: p  0.42).
We first examined the effect of GCH1 haplotype on the
evels of plasma biopterins. Patients with the X haplotype
ad significantly lower plasma levels of both BH4 and total
iopterins than patients homozygous for the common O
aplotype; median plasma BH4 levels in patients with XX
enotype were reduced by approximately 80% compared
ith OO patients. Indeed, plasma BH4 and total biopterin
evels were reduced in a striking allele-dependent manner
rom OO, XO, and XX genotypes (Fig. 1). Because vascular
iopterin levels are likely more important for eNOS
egulation, and could plausibly be differentially regulated
rom plasma biopterin levels, we next sought to examine
he effect of GCH1 haplotype on vascular biopterins, in
oth SV and IMA. The presence of the X haplotype was
ssociated with significantly lower levels of vascular BH4
nd total biopterins in both SV and IMA (Fig. 1). These
ndings suggest a direct effect of this GCH1 haplotype on
iopterin synthesis.
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Figure 1 Effect of GCH1 Haplotype on Plasma/Vascular BH4
The presence of the haplotype (XO or XX) was associated with significantly
lower levels of plasma tetrahydrobiopterin (BH4) (A) and total biopterins (tBio)
(B). A similar effect was also observed in saphenous veins (SV) (C and D) and
internal mammary arteries (IMA) (E and F).
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GCH1 Haplotypes and Vascular Biopterins July 8, 2008:158–65To investigate whether the effect of the GCH1 haplotype on
iopterin levels was mediated by changes in GCH1 gene
xpression, we performed RT-PCR to quantify GCH1 mes-
enger (m)RNA in samples of SV and IMA from patients with
ifferent GCH1 genotypes. We observed that the XX genotype
as associated with significantly reduced vascular GCH1 ex-
ression compared with the OO genotype (Fig. 2). Further-
ore, vascular GCH1 mRNA levels across all genotypes were
ignificantly correlated with both plasma (r  0.394, p 
.010) and vascular (r  0.336, p  0.042) BH4 levels.
We next sought to investigate how these genetically deter-
ined differences in biopterin levels might influence NO-
ediated endothelial function and vascular superoxide produc-
ion. Because homozygosity for the X haplotype is relatively
ncommon (2% of our population), we used a recessive model,
omparing patients with or without X haplotype. In support of
he recessive model, patients with at least 1 X haplotype (i.e.,
O or XX genotypes) had significantly lower BH4 and total
iopterins than OO patients, in both plasma (16.6 [5.2 to 28.3]
nd 41.2 [23.4 to 54.9] nmol/l vs. 21.57 [12.1 to 45.24] and
8.3 [32.6 to 76.4] nmol/l, p 0.05 for both) and SV (7.1 [2.2
o 9.3] and 32 [22 to 93] nmol/l vs. 11.0 [5.7 to 17.8] and 43
24 to 76] nmol/g, p  0.05 for both).
Vascular superoxide production was significantly in-
reased in X haplotype carriers (Fig. 3). To explore the
pecific contribution of eNOS coupling, we quantified the
ifference in vascular superoxide production after NOS
nhibition by L-NAME. Incubation of vessels with
-NAME inhibited superoxide production to a signifi-
antly greater extent in X haplotype carriers than in OO
omozygotes (Fig. 3). Increased oxidative stress in X hap-
otype carriers was also supported by the observation of
Figure 2 Effect of GCH1 Haplotype
on Vascular GTPCH mRNA Levels
The presence of the XX genotype was associated with significantly lower mes-
senger ribonucleic acid (mRNA) levels of GTPCH compared with OO genotype.
Shown are the data derived from 23 saphenous veins (SVs) and 17 internal
mammary arteries (IMAs). *p  0.05 versus OO.(ower BH4:total biopterin ratio, and increased circulating
evels of oxidized LDL (Fig. 3).
To investigate how this GCH1 haplotype and the asso-
iated differences in biopterin levels modulate NO-
ediated endothelial function, we quantified the vasomotor
esponses of vessel segments to ACh in an organ bath
ystem. Vasorelaxation responses to ACh were significantly
educed in X haplotype carriers than in OO homozygotes,
hereas endothelium-independent vasomotor responses to
he direct NO donor, SNP, were identical between geno-
ypes (Fig. 3).
ultivariate analysis. Because BH4 levels and endothelial
unction may potentially be altered by many factors, we used
ultivariate analysis to further investigate the relationships
etween the GCH1 haplotype and biopterin levels, taking
nto account other clinical and demographic factors. Pres-
nce of the X haplotype was an independent predictor of
educed BH4 levels in both plasma and vascular tissue
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Figure 3 Effect of GCH1 Haplotype on Vascular Superoxide,
Oxidative Stress, and Endothelial Function
The presence of the X haplotype was associated with higher total superoxide
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) production (A) and greater L-NAME-inhibitable delta[O2
] (B) in human
saphenous veins. The X haplotype was also associated with significantly lower
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saphenous veins, although it had no impact on the vasomotor responses to
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aplotype was independently associated with increased vas-
ular superoxide production (SV:  [SE] 1.196 [0.573], p
.04) and with reduced vasorelaxations to ACh (SV:  [SE]
5.304 [2.355], p  0.026). Of the other additional
emographic and clinical factors, diabetes mellitus was
ndependently associated with increased vascular superoxide
roduction ( [SE] 1.520 [0.619], p  0.016) and with
educed ACh vasorelaxations ( [SE] 5.442 [2.313], p 
.020), and hypercholesterolemia with reduced ACh va-
orelaxations ( [SE] 7.703 [2.236], p  0.001). Female
ender was independently associated with reduced ACh
asorelaxations ( [SE] 7.646 [2.741], p  0.006) and
ith reduced BH4 levels ( [SE] 5.24 [2.25], p  0.022).
iscussion
n this study we have identified a striking effect of a novel
aplotype of the GCH1 gene on both plasma and vascular
H4 levels in patients with CAD, mediated through altered
CH1 expression. In turn, we have shown that these
enetically determined differences in BH4 availability are
ndependent and strong predictors of key features of
ndothelial function, including aspects of eNOS coupling
uch as vascular superoxide production and NO-mediated
asorelaxation.
Tetrahydrobiopterin is an essential cofactor for eNOS
unction in the vascular endothelium, with increasingly
ecognized roles in the pathogenesis of vascular disease
tates through effects on eNOS coupling (1) in both the
ascular wall and in circulating endothelial progenitor cells
31). However, little is known about the pathophysiologic
ontrol of endothelial BH4 levels in humans. In disease
tates such as atherosclerosis (32), diabetes mellitus (17,31),
ypertension (12), or insulin resistance (33,34), vascular
H4 deficiency seems to be mediated, at least in part, by the
ncreased intracellular oxidation of BH4 to BH2 and B by
eactive oxygen species (such as ONOO) (7,32). However,
ther studies suggest that changes in BH4 biosynthesis,
hrough regulation of the rate-limiting enzyme GTPCH
35), may also be an important mechanism regulating
ascular BH4 bioavailability (34,36). The GCH1 gene,
ncoding GTPCH, is expressed in several cell types, such as
acrophages (37), endothelial cells (38), and others. How-
ver, it has been unclear to what extent altered GCH1
xpression in the human vascular wall is related to differ-
nces in vascular BH4 levels, or to aspects of endothelial
unction in subjects with vascular disease. We have now
sed the genetic strategy of Mendelian randomization in
umans to investigate the functional effects of intrinsic
ifferences in vascular GCH1 expression.
The importance of GCH1 expression and GTPCH en-
ymatic activity in regulating BH4 availability is well estab-
ished. Loss-of-function mutations of GCH1 cause severe
H4 deficiency, resulting in diseases such as dopa-esponsive dystonia (OMIM 128230) and variant phenyl- tetonuria (OMIM 233910), because of dysfunction of the
H4-dependent enzymes tyrosine hydroxylase and phenyl-
lanine hydroxylase. Experimental mouse models with al-
erations in systemic or vascular-specific GCH1 expres-
ion (10,16) have shown that GTPCH is a key regulator
f vascular BH4 levels in vivo. For example, the hph-1
ouse has an ENU mutant allele that maps to the GCH1
ocus, but without mutations in the either the GCH1 coding
equence or minimal promoter (10). The hph-1 allele
esults in reduced GCH1 expression and reduced BH4
evels, an intermediate phenotype in heterozygote ani-
als and functional defects in both neurotransmitter and
O synthesis (16).
We have recently shown that a specific GCH1 haplotype
whose presence we define as X and absence as O) confers
ignificant reduction in the induction of GCH1 expression
nd biopterin levels in leukocytes after a forskolin or
ipopolysaccharide challenge (18,19). Furthermore, this
CH1 haplotype is associated with changes in pain percep-
ion and the severity of postoperative pain, likely because of
ifferences in GCH1 expression after nerve injury (18,19). In
ddition, systemic inflammation seems to be a key regulator
f biopterin synthesis in patients with CAD because plasma
iopterins are correlated with plasma CRP (39). We have
ow shown that the presence of the X haplotype is associ-
ted with lower levels of both plasma BH4 and total
iopterins (which is the sum of BH4, BH2, and B,
eflecting the overall biosynthetic activity of GTPCH) in
atients with multivessel CAD. These patients represent a
odel of moderate inflammatory stimulation (mean CRP
.2 mg/l, with range from 0.12 to 15.5 mg/l), consistent
ith the effect of the haplotype on the regulation of GCH1
xpression in white blood cells in response to lipopolysac-
haride exposure. This effect was observed not only in the
ncommon XX genotype (2% of our population), but also in
he X haplotype carriers (XO genotype; 27.4% of the
opulation), suggesting that the X haplotype may be an
mportant and common factor in regulating circulating
iopterin levels in patients with CAD. Importantly, we
bserved that the effect of the X haplotype on plasma BH4
as paralleled by an effect on vascular BH4, and on GCH1
RNA levels in vascular tissue. It seems most likely that the
unctional SNP or SNPs in the GCH1 X haplotype block
ill have effects on GCH1 expression, for example through
ffects on transcription, or on GCH1 mRNA stability and
ranslation. However, we have no evidence that any of the
NPs used to define the GCH1 X haplotype have any direct
unctional effects. Indeed, the SNPs chosen to screen the
CH1 gene were not selected on the basis of possible
unctional importance. Further recent evidence suggests
hat another SNP, located in the 3= UTR of the GCH1
ene, is also associated with reduced biopterin-dependent
ffects (40). Whether this SNP is part of the same or
nother haploblock as the X haplotype identified in our
tudies remains to be seen. Further studies will be required
o ascertain which component SNP or SNPs confer the
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ffect might be mediated.
Our observations suggest that GCH1 haplotype plays a
otentially important role in regulating vascular BH4 bio-
vailability in CAD. More generally, our results highlight
he central role of GTPCH, and GCH1 gene expression in
articular, as key regulators of biopterin availability in
umans, and in the functional responses of the vascular
ndothelium in vascular disease states. In the vascular
ndothelium, BH4 mediates coupling of oxygen reduction
o heme-catalyzed L-arginine oxidation to form NO and
-citrulline (2). Therefore, BH4 deficiency is proposed to
ead to eNOS uncoupling, resulting in decreased NO
ioavailability and increased production of superoxide rad-
cals from the uncoupled enzymatic form (41). A BH4
eficiency is associated with eNOS uncoupling in experi-
ental models (17), resulting in increased superoxide pro-
uction and decreased NO bioavailability in the vascular
all (41). Indirect evidence from previous clinical studies
uggested that increased BH4 bioavailability is associated
ith improved endothelial function and eNOS coupling
5,6). However, the impact of endogenous BH4 levels on
ascular function in patients with vascular disease has
emained uncertain.
The identification of a GCH1 haplotype with a major
ffect on endogenous BH4 levels in patients with CAD
rovided us with a novel means to test the functional effect
n BH4 in the vascular wall. Indeed, we observed that the
resence of the X haplotype was associated with both higher
ascular superoxide and a greater L-NAME inhibitable
raction of superoxide, representing superoxide derived from
ncoupled eNOS. This finding supports the hypothesis that
ascular BH4 regulates eNOS coupling in vessels from
atients with CAD. The impact of the X haplotype on
ascular redox state was also reflected in the systemic levels
f ox-LDL and the BH4/total biopterin ratio, both systemic
iomarkers of the overall oxidative stress status. To further
valuate the impact of the X haplotype on eNOS function,
e examined its effect on the vasomotor responses of the
ame vessels to acetylcholine, observing that the X haplotype
as associated with reduced vasorelaxations to acetylcholine,
mplying that it has a direct impact on NO bioavailability and
ndothelial function in these vessels. Importantly, we observed
hat the effects of this haplotype on vascular BH4, superoxide
roduction, eNOS coupling, and endothelial function were
ndependent of the presence of other risk factors for
therosclerosis, suggesting that this haplotype may prove to
e an independent risk factor for atherosclerosis.
tudy limitations. Some limitations of the present study
eed to be acknowledged. We were unable to evaluate the
ffect of GCH1 haplotypes in vessels from healthy individ-
als because these measurements require surgical material
segments of SV and IMA grafts used in CABG) that is not
vailable from healthy individuals. We evaluated endothelial
unction in isolated SV segments, rather than arterial
egments, because of the limited quantity of arterial tissuevailable from IMA grafts. However, we have used SV in
he past as a reliable model system for the study of human
ascular endothelium (5,6,20). Finally, our use of lucigenin-
nhanced chemiluminescence provides only a measure of
verall vascular superoxide generation rather than identify-
ng the specific cell types involved.
onclusions
n conclusion, we have shown that a novel haplotype of the
CH1 gene is a major determinant of BH4 bioavailability in
oth plasma and vascular endothelium in patients with
AD. Our findings show that GCH1 expression is a key
egulator of vascular biopterin levels, and in turn an impor-
ant determinant of vascular oxidative stress and endothelial
unction. Genetic differences in BH4 availability could have
otentially important effects on vascular disease pathogen-
sis, and provide a means to test the effects of BH4 on
linical outcomes and cardiovascular risk, a question that
ill need to be addressed in large case-control and prospec-
ive follow-up studies.
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